^
BIOMARKER:

EGFR expression

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR expression
Lung Non-Small Cell Squamous Cancer
necitumumab
Sensitive: A1 - Approval
EGFR expression
CRC
cetuximab
Sensitive: A1 - Approval
EGFR expression
Chordoma
lapatinib
Sensitive: A2 - Guideline
EGFR expression
NSCLC
erlotinib + ramucirumab
Sensitive: A2 - Guideline
EGFR expression
NSCLC
erlotinib
Sensitive: B - Late Trials
EGFR expression
CRC
panitumumab
Sensitive: B - Late Trials
EGFR expression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: B - Late Trials
EGFR expression
NSCLC
gefitinib
Sensitive: B - Late Trials
EGFR expression
SCCHN
cetuximab
Sensitive: C1 - Off-label
EGFR expression
NSCLC
durvalumab
Sensitive: C2 – Inclusion Criteria
EGFR expression
Ovarian Cancer
gefitinib
Resistant: C3 – Early Trials
EGFR expression
NSCLC
sintilimab
Sensitive: C3 – Early Trials
EGFR expression
NSCLC
PD-L1 inhibitor
Resistant: C3 – Early Trials
EGFR expression
Pancreatic Adenocarcinoma
trastuzumab + erlotinib
Sensitive: C3 – Early Trials
EGFR expression
NSCLC
osimertinib
Sensitive: C3 – Early Trials
EGFR expression
Lung Non-Squamous Non-Small Cell Cancer
gefitinib
Sensitive: C3 – Early Trials
EGFR expression
LUAD
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
EGFR expression
NSCLC
anlotinib + APL-502
Sensitive: C3 – Early Trials
EGFR expression
NSCLC
cetuximab + afatinib
Resistant: C3 – Early Trials
EGFR expression
Triple Negative Breast Cancer
lapatinib
Sensitive: C3 – Early Trials
EGFR expression
LUAD
afatinib
Sensitive: C4 – Case Studies
EGFR expression
GBM
paclitaxel
Sensitive: D – Preclinical
EGFR expression
GBM
selumetinib
Sensitive: D – Preclinical
EGFR expression
Glioma
gefitinib
Sensitive: D – Preclinical
EGFR expression
SCCHN
vandetanib
Sensitive: D – Preclinical
EGFR expression
Pancreatic Cancer
afatinib
Sensitive: D – Preclinical
EGFR expression
Triple Negative Breast Cancer
AFM24
Sensitive: D – Preclinical